6533b830fe1ef96bd1297293

RESEARCH PRODUCT

The Relevance of Noninvasive Tools To Assess Fibrosis in Non-Alcoholic Fatty Liver Disease.

Federica SpatolaGrazia PennisiSalvatore PettaAntonina GiammancoCiro Celsa

subject

Liver Cirrhosismedicine.medical_specialtyCirrhosisCarcinoma HepatocellularBiopsyDiseaseGastroenterology03 medical and health sciences0302 clinical medicineFibrosisNon-alcoholic Fatty Liver DiseaseInternal medicineDrug DiscoverymedicineHumansPharmacologymedicine.diagnostic_testbusiness.industryFatty liverLiver Neoplasmsnutritional and metabolic diseasesBiomarkers FibroScan Fibrosis MRE MRI NAFLD NASH Non-invasive testsmedicine.diseasedigestive system diseasesLiver030220 oncology & carcinogenesisLiver biopsyHepatocellular carcinoma030211 gastroenterology & hepatologySteatohepatitisbusinessHepatic fibrosis

description

Non-alcoholic fatty liver disease (NAFLD) is a growing cause of chronic liver diseases worldwide, involving about 25% of people. NAFLD incorporates a large spectrum of pathological conditions, from simple steatosis to non-alcoholic steatohepatitis (NASH), cirrhosis and its complications include hepatic decompensation and hepatocellular carcinoma (HCC). This progression occurs, over many years, in an asymptomatic way, until advanced fibrosis appears. Thus, the differentiation of NASH from simple steatosis and identification of advanced hepatic fibrosis are key issues. To date, the histological assessment of fibrosis with liver biopsy is the gold standard, but obviously, invasiveness is the greater threshold. In addition, rare but potentially life-threatening complications, poor acceptability, sampling variability and cost maybe restrict its use. Furthermore, due to the epidemic of NAFLD worldwide and several limitations of liver biopsy evaluation, noninvasive assessment tools to detect fibrosis in NAFLD patients are needed.

10.2174/1381612826666200521133307https://pubmed.ncbi.nlm.nih.gov/32436818